EUVIMEDEUVIMED entdecken
Crossref

Phase III Study to Evaluate the Efficacy and Safety of Two Novel Fixed-Dose Vaginal Ovule Formulations in the Treatment of Various Vaginal Infections: One-Shot Study Running Title: Phase III study of two novel vaginal ovules

Erol Tavmergen, Ferruh Acet, Pınar Yalçın Bahat, Burak Karadağ, Levent Yaşar, Ahmet Kale, Serpil Aydoğmuş, Berna Dilbaz, Cüneyt Eftal Taner, Fatih Durmuşoğlu, Feriha Çilli

Archives of Gynaecology and Women Health · 2024

DOI: 10.58489/2836-497x/024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Gynaecology and Women Health, 2024. Verfasst von Erol Tavmergen und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to evaluate the efficacy and safety of two novel formulations: one containing fenticonazole nitrate 600 mg + tinidazole 1000 mg + lidocaine 100 mg (Formulation A) and the other with fenticonazole nitrate 600 mg + tinidazole 2000 mg + lidocaine 100 mg (Formulation B) in the treatment of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomonas vaginitis (TV), and mixed vaginal infections (MVIs) in comparison to comparator medication (Gynomax® XL). Materials and methods: This phase III study enrolled 562 adult, pre-menopausal patients with BV, VVC, TV, or MVIs. Of these, 544 received the study medication (included in the safety analysis), and 440 completed the study (included in the efficacy analysis). Patients were randomized into Formulation A, Formulation B, or comparator medication arms. Follow-up visits were conducted two weeks post-treatment, with clinical and microbiological evaluations.

Results

Initial clinical diagnoses indicated BV (62.0%), VVC (19.8%), MVIs (15.5%), and TV (2.7%). High clinical recovery rates were observed with Formulation A (96.7% of BV, 81.8% of VVC, and 96.3% of MVIs), Formulation B (97.7% of BV, 88.2% of VVC, 90.9% of MVIs), and comparator medication (98.9% of BV, 90.3% of VVC, 100.0% of MVIs). None of the patients discontinued medications due to an adverse event or intolerability.

Conclusion

All formulations are considered as safe, well-tolerated, and highly effective for treating BV, VVC, and MVIs. Formulation A or B may be particularly advantageous due to anticipated greater patient compliance with their single-dose administration.

Zitieren

APA

Tavmergen, E., Acet, F., Bahat, P. Y., Karadağ, B., Yaşar, L., Kale, A., Aydoğmuş, S., Dilbaz, B., Taner, C. E., Durmuşoğlu, F., & Çilli, F. (2024). Phase III Study to Evaluate the Efficacy and Safety of Two Novel Fixed-Dose Vaginal Ovule Formulations in the Treatment of Various Vaginal Infections: One-Shot Study Running Title: Phase III study of two novel vaginal ovules. Archives of Gynaecology and Women Health. https://doi.org/10.58489/2836-497x/024

Vancouver

Tavmergen E, Acet F, Bahat PY, Karadağ B, Yaşar L, Kale A, et al. Phase III Study to Evaluate the Efficacy and Safety of Two Novel Fixed-Dose Vaginal Ovule Formulations in the Treatment of Various Vaginal Infections: One-Shot Study Running Title: Phase III study of two novel vaginal ovules. Archives of Gynaecology and Women Health. 2024. doi:10.58489/2836-497x/024

BibTeX
@article{Tavmergen2024,
  author = {Tavmergen, Erol and Acet, Ferruh and Bahat, Pınar Yalçın and Karadağ, Burak and Yaşar, Levent and Kale, Ahmet and Aydoğmuş, Serpil and Dilbaz, Berna and Taner, Cüneyt Eftal and Durmuşoğlu, Fatih and Çilli, Feriha},
  title = {Phase III Study to Evaluate the Efficacy and Safety of Two Novel Fixed-Dose Vaginal Ovule Formulations in the Treatment of Various Vaginal Infections: One-Shot Study Running Title: Phase III study of two novel vaginal ovules},
  journal = {Archives of Gynaecology and Women Health},
  year = {2024},
  doi = {10.58489/2836-497x/024}
}
Kostenlos starten →